AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is a pre-commercial stage biopharmaceutical company developing immunological drugs, primarily Ampligen, an experimental double-stranded RNA immunomodulator being tested for advanced pancreatic cancer and post-COVID-19 conditions, along with Alferon N Injection, an FDA-approved interferon product generating minimal revenue. The company's revenue model consists almost entirely of external financing through equity offerings and warrant issuances, as it generates negligible operating revenues and conducts Phase 2 clinical trials in partnership with leading research institutions and clinical research organizations. AIM targets patient populations across multiple disease areas and seeks pharmaceutical partners for co-development and licensing arrangements, pursuing capital-rich collaborators to advance Ampligen through clinical development toward potential commercialization.